Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Cetirizine for Female Androgenetic Alopecia
NCT04481412Phase 3Completed
- Sponsor
- Cairo University
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cetirizine in androgenetic alopecia (AGA) (2 arms), sponsored by Cairo University. Primary endpoints: Change from baseline in number of terminal hairs and vellus hair at 24 weeks, Change from baseline in hair shaft thickness at 24 weeks and 2 more. Started Jul 2020; status: completed.
02
Drugs
cetirizine
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04481412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481412.